US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

MiniMed Group, Inc. (MMED): Medtronic Spinoff Falls on First Day Despite Deep IPO Discount

MiniMed (MMED US): Low Passive Fund Flows Due to Low Float

MiniMed Group, Inc. (MMED): Long-Awaited Medtronic Diabetes Spin-Off Sets Terms for IPO

MiniMed Group, Inc. (MMED): Peeking at the IPO Prospectus of Medtronic's Diabetes Spin-Off

IPOs and Secondary Offerings

Equity Capital Markets

<ul>
<li>MiniMed seeks $7.0–$7.9B valuation as Medtronic retains 90% ownership post-IPO, supported by strong balance sheet and credit facility.</li>
<li>Only end-to-end Smart Dosing ecosystem spanning CGMs, pumps, algorithms, and software with expanding third-generation pipeline.</li>
<li>Trades below peers on forward EBITDA, though royalty agreements and reimbursement pressures warrant cautious near-term stance.</li>
</ul>


MiniMed seeks $7.0–$7.9B valuation as Medtronic retains 90% ownership post-IPO, supported by strong balance sheet and credit facility.
Only end-to-end Smart Dosing ecosystem spanning CGMs, pumps, algorithms, and software with expanding third-generation pipeline.
Trades below peers on forward EBITDA, though royalty agreements and reimbursement pressures warrant cautious near-term stance.


미니메드 그룹(MMED): 규모의 경제, 반복 수익, 그리고 로열티 문제를 다룬 분사 IPO 스토리